- Report
- October 2024
- 181 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,784GBP
- Report
- May 2024
- 131 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- January 2022
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- July 2023
- 80 Pages
Global
From €3500EUR$4,120USD£3,106GBP
Aranesp (darbepoetin alfa) is a hematological drug used to treat anemia caused by chronic kidney disease. It is a recombinant form of erythropoietin, a hormone produced by the kidneys that stimulates the production of red blood cells. Aranesp is administered by injection and is used to reduce the need for red blood cell transfusions in patients with anemia. It is also used to treat anemia caused by chemotherapy in patients with certain types of cancer.
Aranesp is a part of a larger market of hematological drugs, which includes other erythropoietin stimulating agents (ESAs) such as epoetin alfa and epoetin beta. These drugs are used to treat anemia caused by a variety of conditions, including chronic kidney disease, cancer, and HIV/AIDS.
The companies in the Aranesp market include Amgen, Inc., Johnson & Johnson, and Roche Holding AG. Show Less Read more
